High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER

 
• By Cathy Kelly
  
Andrii Yalanskyi/Shutterstock.com

More from Pricing Debate

More from Market Access